A Study of Lisaftoclax in Combination With Azacitidine in People With Higher-Risk Myelodysplastic Syndrome

Full Title

A Global Multicenter, Double-Blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HRMDS) (GLORA-4)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Xin Wang’s office at 646-608-4365.

Protocol
26-246
Phase
Phase III (phase 3)
Investigator
Xin Wang
Co-Investigators
Eytan M. Stein
Diseases
Hematology › Myelodysplastic Syndrome
Leukemia › Myelodysplastic Syndrome
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT06641414
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description